Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients

British Journal of Cancer

Volumn 108, Issue 1, 2013, Pages 139-148

  Willder, J M ^a   Heng, S J ^a   McCall, P ^a   Adams, C E ^a   Tannahill, C ^a   Fyffe, G ^a   Seywright, M ^b   Horgan, P G ^a   Leung, H Y ^a,c,d   Underwood, M A ^d   Edwards, J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^d SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Androgen receptor; biomarker; phosphorylation; prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; CYCLIN DEPENDENT KINASE 1; ROSCOVITINE;

AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

AGED; CDC2 PROTEIN KINASE; DISEASE-FREE SURVIVAL; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PURINES; RECEPTORS, ANDROGEN; RECURRENCE; SERINE; TUMOR MARKERS, BIOLOGICAL;

EID: 84872587781     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.480     Document Type: Article

References (30)

1. Anderson NG, Maller JL, Tonks NK, Sturgill TW (1990) Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature 343: 651-653.
2. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ (2003) Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 63: 1981-1989.
3. Bell WC, Myers RB, Hosein TO, Oelschlager DK, Grizzle WE (2003) The response of extracellular signal-regulated kinase (ERK) to androgen-induced proliferation in the androgen-sensitive prostate cancer cell line, LNCaP. Biotech Histochem 78: 11-16.
4. Blok LJ, de Ruiter PE, Brinkmann AO (1998) Forskolin-induced dephosphorylation of the androgen receptor impairs ligand binding. Biochemistry 37: 3850-3857.
5. Chen S, Gulla S, Cai C, Balk SP (2012) Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. J Biol Chem 287(11): 8571-8583.
6. Chen S, Xu Y, Yuan X, Bubley GJ, Balk SP (2006) Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Nat Acad Sci USA 103: 15969-15974.
7. Chymkowitch P, Le May N, Charneau P, Compe E, Egly JM (2011) The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process. EMBO J 30(3): 468-479.
8. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB, Thompson I (2007) Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177: 540-545.
9. Diallo JS, Aldejmah A, Mouhim AF, Fahmy MA, Koumakpayi IH, Sircar K, Begin LR, Mes-Masson AM, Saad F (2008) Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis. BJU Int 101: 1302-1309.
10. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
11. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, Keller ET (2003) Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 95: 878-889.
12. Gioeli D, Black BE, Gordon V, Spencer A, Kesler CT, Eblen ST, Paschal BM, Weber MJ (2006) Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol Endocrinol (Baltimore, MD) 20: 503-515.
13. Gioeli D, Paschal BM (2012) Post-translational modification of the androgen receptor. Mol Cell Endocrinol 352: 70-78.
14. Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufman Jr RP, Ross JS (1997) The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer 80: 753-763.
15. Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R, Tam L, Munro AF, Dunne B, Bartlett JM (2006) Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48: 787-794.
16. Kuiper GG, Brinkmann AO (1995) Phosphotryptic peptide analysis of the human androgen receptor: detection of a hormone-induced phosphopeptide. Biochemistry 34: 1851-1857.
17. McCarty Jr. KS, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, Konrath J, Soper JT, Budwit DA, Creasman WT et al. (1986) Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 46: 4244s-4248s.
18. Mistry M, Parkin DM, Ahmad AS, Sasieni P (2011) Cancer incidence in the United Kingdom: projections to the year 2030. Br J Cancer 105: 1795-1803.
19. Mukherjee R, McGuinness DH, McCall P, Underwood MA, Seywright M, Orange C, Edwards J (2011) Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer. Br J Cancer 104: 1920-1928.
20. Obenauer JC, Cantley LC, Yaffe MB (2003) Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res 31: 3635-3641.
21. Ohta T, Okamoto K, Isohashi F, Shibata K, Fukuda M, Yamaguchi S, Xiong Y (1998) T-loop deletion of CDC2 from breast cancer tissues eliminates binding to cyclin B1 and cyclin-dependent kinase inhibitor p21. Cancer Res 58: 1095-1098.
22. Ponguta LA, Gregory CW, French FS, Wilson EM (2008) Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. J Biol Chem 283: 20989-21001.
23. Powell SM, Christiaens V, Voulgaraki D, Waxman J, Claessens F, Bevan CL (2004) Mechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate. Endocr Relat Cancer 11: 117-130.
24. Roach 3rd M, Hanks G, Thames Jr. H, Schellhammer P, Shipley WU, Sokol GH, Sandler H (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65: 965-974.
25. Shigemura K, Isotani S, Wang R, Fujisawa M, Gotoh A, Marshall FF, Zhau HE, Chung LW (2009) Soluble factors derived from stroma activated androgen receptor phosphorylation in human prostate LNCaP cells: roles of ERK/MAP kinase. Prostate 69: 949-955.
26. Tyagi RK, Lavrovsky Y, Ahn SC, Song CS, Chatterjee B, Roy AK (2000) Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol Endocrinol (Baltimore, MD) 14: 1162-1174.
27. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC (2000) HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60: 6841-6845.
28. Wong HY, Burghoorn JA, Van Leeuwen M, De Ruiter PE, Schippers E, Blok LJ, Li KW, Dekker HL, De Jong L, Trapman J, Grootegoed JA, Brinkmann AO (2004) Phosphorylation of androgen receptor isoforms. Biochem J 383: 267-276.
29. Zhou ZX, Kemppainen JA, Wilson EM (1995) Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol Endocrinol Baltimore, MD 9: 605-615.
30. Zong H, Chi Y, Wang Y, Yang Y, Zhang L, Chen H, Jiang J, Li Z, Hong Y, Wang H, Yun X, Gu J (2007) Cyclin D3/CDK11p58 complex is involved in the repression of androgen receptor. Mol Cell Biol 27: 7125-7142.